The announcement of a stock offering typically leads to a decrease in stock price due to dilution concerns. The significant drop of 39% reflects investor reaction to the uncertainty of the offering's size and terms. The use of funds for commercialization and clinical studies is positive long-term, but the immediate impact is negative. The RSI indicates oversold conditions, suggesting potential for future recovery.